Life sciences briefing: Tuesday, Oct. 2, 2007

Want to master the CMO role? Join us for GrowthBeat Summit on June 1-2 in Boston, where we'll discuss how to merge creativity with technology to drive growth. Space is limited and we're limiting attendance to CMOs and top marketing execs. Request your personal invitation here!

Featured companies: Change:healthcare, Gemin X Biotechnologies, Ipsogen, the Practice

change-healthcare-logo.jpgChange:healthcare raises $1M for health 2.0 sites — Nashville, Tenn.-based change:healthcare, a provider of Web-based health information, raised $1 million in a first funding round. The investment firm Solidus, also based in Nashville, provided the cash. There’s no release, but the Nashville Business Journal did run this story.

Change:healthcare operates two “health 2.0″ Web sites designed to empower individuals by helping them better navigate the healthcare system. offers a searchable database of doctors and hospitals, while MedBillManager is a fee-based service for helping individuals and families manage a confusing welter of medical bills and insurance statements.

gemin-x-logo.jpgCancer-drug developer Gemin X garners $72.6M — Montreal’s Gemin X Biotechnologies, a biotech developing a variety of cancer drugs, has raised $72.6 million of a planned $114.7 million third funding round, VentureWire reports (subscription required).

The wire service cited a regulatory filing for its report. No investors were reported on that filing, although the company did just appoint Eric Roberts, a managing director of Caxton Advantage, to its board. Understandably enough, such appointments usually reflect the desire of a VC or, in this case, a hedge-fund affiliate, to keep a close eye on a significant investment.

Gemin X develops cancer drugs that, for the most part, interfere or promote the process of programmed cell death, or apoptosis.

Physician-office manager The Practice raises £1.4M — The Practice, a U.K. firm that manages doctors’ offices, raised £1.4 million ($2.9 million). MMC Ventures provided the funding. The proceeds will allow the company to expand its operations.

Ipsogen draws in $3.4M for diagnostic tests — Ipsogen, a Marseille, France, biotech focused on cancer diagnostics, raised $3.4 million, VentureWire reports. Investors included Matignon Technologies, Societe Generale Asset Management, Sofipaca and Connecticut Innovations, which provided $680,000 to help the company’s U.S. subsidiary expand its headquarters in New Haven, Conn. Connecticut Innovations is a quasi-public economic-development agency. The company’s lead product is a diagnostic for leukemia.

VentureBeat’s VB Insight team is studying email marketing tools. Chime in here, and we’ll share the results.